You are being asked to participate in this research study because you have been diagnosed with breast cancer and considered for immunotherapy. This study will investigate your response to immunotherapy.

Are you interested in improving your physical health and wellbeing during or after cancer treatment? If so, our free 12- week exercise program might be a good fit for you! We are creating a registry of adults with a cancer diagnosis who have gone through our program.

Do you have triple-negative breast cancer that either came back or did not improve after initial cancer treatment? If so, you may be able to take part in this gene therapy research study to learn more about using your own modified immune cells as a possible treatment.

To find out if the study drug AZD9829 is safe and tolerable and effective in treating blood cancer.

Do you have Stage II or III Breast cancer? If you have enough tissue from your breast cancer diagnosis to send for Mammaprint genomic testing, you may be able to take part in this research study. In this study, we want to learn more about adding an immunotherapy drug, durvalumab, to your chemotherapy treatment. The Mammaprint testing is conducted at no cost to you and the cost of durvalumab is covered.

Can we extend your life after the diagnosis of your cancer in the stomach, esophagus, or gastroesophageal junction by adding a third chemotherapy drug to the usual combination of two chemotherapy drugs? We are doing this study because we want to find out if this approach is better or worse than the usual approach for treatment of your cancer in the stomach, esophagus, or gastroesophageal junction. The usual approach is defined as care most people get for cancer in the stomach, esophagus, or gastroesophageal junction.

In this study, we want to determine if dietary intervention is feasible for patients being treated for leukemia or lymphoma.

In this study, we want to find out if a combination of 3 different study drugs (Cabozantinib, Ipilimumab, and Nivolumab) will affect the progression of Soft Tissue Sarcoma.

Have you been diagnosed with metastatic triple negative breast cancer and have had progression of your cancer during or following your most recent cancer treatment? If so, you may be eligible for a study looking at the combination of two investigational drugs with doxil for patients with metastatic triple negative breast cancer.

Do you have intermediate risk prostate cancer and don't want to undergo surgery? You may be able to participate in a research study comparing therapy based on genetic testing.